OP
TEVA icon

ORG Partners’s Teva Pharmaceuticals TEVA Stock Holding History

ORG Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500
Closed -$11K – 1591
2024
Q4 		$11K Hold
500
– – ﹤0.01% 871
2024
Q3 		$9.01K Hold
500
– – ﹤0.01% 803
2024
Q2 		$8.17K Hold
500
– – ﹤0.01% 1291
2024
Q1 		$6.96K Buy
+500
New +$6.3K 0.01% 314
2023
Q4 		– Sell
-500
Closed -$5.1K – 1339
2023
Q3 		$5.1K Hold
500
– – ﹤0.01% 949
2023
Q2 		$3.74K Buy
+500
New +$4.05K ﹤0.01% 1123

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

ORG Partners's TEVA Position: Q1 2025 in Review

ORG Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 500 shares — an estimated $11K sold.

ORG Partners first reported a position in TEVA in Q2 2023 and held it in 6 quarters. The position peaked at $11K in Q4 2024. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • ORG Partners reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • ORG Partners sold 500 Teva Pharmaceuticals shares in Q1 2025, an estimated $11K.
  • ORG Partners first reported a position in Teva Pharmaceuticals in Q2 2023 and held it in 6 quarters.
  • ORG Partners's Teva Pharmaceuticals position peaked at $11K in Q4 2024.
  • 560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on ORG Partners's 13F filing for Q1 2025, filed 21 Apr 2025.